Nzs Capital, LLC Dexcom Inc Transaction History

Nzs Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$114.22 - $140.1 $2.7 Million - $3.32 Million	23,665 Added 13.79%	195,307 $27.1 Million
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $843,751 - $1.39 Million	11,177 Added 6.97%	171,642 $21.3 Million
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $2.91 Million - $4.66 Million	33,818 Added 26.7%	160,465 $15 Million
Q2 2023 Aug 11, 2023	BUY	$112.47 - $130.98 $203,458 - $236,942	1,809 Added 1.45%	126,647 $16.3 Million
Q1 2023 May 12, 2023	BUY	$104.0 - $122.92 $7.7 Million - $9.1 Million	74,045 Added 145.78%	124,838 $14.5 Million
Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $2.07 Million - $2.99 Million	24,345 Added 92.05%	50,793 $5.75 Million
Q3 2022 Nov 14, 2022	BUY	$76.35 - $94.18 $2.02 Million - $2.49 Million	26,448 New	26,448 $2.13 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Nzs Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Nzs Capital, LLC with notifications on news.